文献速递慢性肾脏病肾小球疾病

达格列净减少CKD患者肾功能急剧下降:DAPA-CKD预设分析

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
PubMed 文献 · Kidney Int · 2021-09-22

DAPA-CKD预设分析评估SGLT2抑制剂对高危CKD伴显著白蛋白尿患者肾功能急剧下降的影响。随机双盲安慰剂对照试验中,2152例患者各接受达格列净10mg/日或安慰剂,中位随访2.4年。达格列净降低两次连续访视间血清肌酐翻倍风险(HR 0.68),急性肾损伤相关严重不良事件无显著差异。

要点

  • 达格列净降低CKD伴白蛋白尿患者血清肌酐翻倍风险(HR 0.68)。
  • 急性肾损伤相关严重不良事件在达格列净组与安慰剂组无显著差异。
  • 基线亚组间达格列净对肾功能急剧下降的效应无异质性。

核心结论

  • 在CKD伴显著白蛋白尿患者中,达格列净降低肾功能急剧下降风险。

研究设计与样本

  • DAPA-CKD预设分析,随机双盲安慰剂对照试验,中位随访2.4年。
  • 成人CKD患者(尿白蛋白肌酐比200-5000 mg/g,eGFR 25-75 mL/min/1.73m2)随机接受达格列净10 mg/日或安慰剂,各2152例。

主要发现

  • 两次连续访视(中位间隔100天)血清肌酐翻倍在达格列净组63例(2.9%)、安慰剂组91例(4.2%),HR 0.68(95%CI 0.49,0.94)。
  • 考虑死亡竞争风险未改变结果。
  • 急性肾损伤相关严重不良事件达格列净组52例(2.5%)、安慰剂组69例(3.2%),HR 0.77(95%CI 0.54,1.10),无显著差异。

关键数值与推荐

  • 肾功能急剧下降预设终点为两次连续研究访视间血清肌酐翻倍。
  • 急性肾损伤相关严重不良事件为研究者报告的事后分析。

临床怎么用

  • 对CKD伴显著白蛋白尿患者,达格列净可减少肾功能急剧下降,支持其肾脏保护作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This pre-specified analysis of DAPA-CKD assessed the impact of sodium-glucose cotransporter 2 inhibition on abrupt declines in kidney function in high-risk patients based on having chronic kidney disease (CKD) and substantial albuminuria. DAPA-CKD was a randomized, double-blind, placebo-controlled trial that had a median follow-up of 2.4 years. Adults with CKD (urinary albumin-to-creatinine ratio 200-5000 mg/g and estimated glomerular filtration rate 25-75 mL/min/1.73m2) were randomized to dapagliflozin 10 mg/day matched to placebo (2152 individuals each). An abrupt decline in kidney function was defined as a pre-specified endpoint of doubling of serum creatinine between two subsequent study visits. We also assessed a post-hoc analysis of investigator-reported acute kidney injury-related serious adverse events. Doubling of serum creatinine between two subsequent visits (median time-interval 100 days) occurred in 63 (2.9%) and 91 (4.2%) participants in the dapagliflozin and placebo groups, respectively (hazard ratio 0.68 [95% confidence interval 0.49, 0.94]). Accounting for the competing risk of mortality did not alter our findings. There was no heterogeneity in the effect of dapagliflozin on abrupt declines in kidney function based on baseline subgroups. Acute kidney injury-related serious adverse events were not significantly different and occurred in 52 (2.5%) and 69 (3.2%) participants in the dapagliflozin and placebo groups, respectively (0.77 [0.54, 1.10]). Thus, in patients with CKD and substantial albuminuria, dapagliflozin reduced the risk of abrupt declines in kidney function.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Cherney D, Postmus D, et al. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int. 2021. PMID: 34560136. doi:10.1016/j.kint.2021.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。